Vera Therapeutics, Inc. 8-KCurrent Reports (8-K / ad hoc)

Financial Statements

Item 8.01 Other Events. As noted in Item 7.01, on September 15, 2026, the Company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgAN at risk for disease progression. Topline results from the final analysis set of 428 patients are presented below. TRUTAKNA Placebo Treatment effect p-value Mean eGFR change from baseline at 52 weeks, mL/min/1.73m 2 -0.1 (95% CI -1.4, 1.2) -5.7 (95% CI -7.0, -4.4) 5.6 (95% CI 3.7, 7.5) <0.0001 Annualized eGFR slope through 104 weeks, mL/min/1.73m 2 /year -0.6 (95% CI -1.6, 0.4) -5.6 (95% CI -6.6, -4.6) 5.0 (95% CI 3.6, 6.5) <0.0001 Composite kidney disease progression event through 104 weeks, n 11 38 Hazard ratio 0.24 (95% CI 0.12, 0.48) 76% risk reduction <0.0001 Dialysis ≥30 days, transplant, or death through 104 weeks, n 0 8 These estimated glomerular filtration rate (“eGFR”) results align with the KDIGO treatment goal to reduce the rate of kidney function decline to the physiologic rate (<1 mL/min/1.73m 2 /year). TRUTAKNA also achieved statistically significant reductions in the hierarchically tested endpoints of proteinuria, galactose-deficient IgA1, and hematuria. TRUTAKNA was well tolerated with a favorable safety profile generally comparable to placebo, consistent with previous results from the ORIGIN program. Rates of overall adverse events and infections or infestations were similar between the TRUTAKNA and placebo groups, and there were no opportunistic infections or clinically relevant hypogammaglobulinemia. 2